| Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations PC Taberlay*, J Achinger-Kawecka*(co-1st), ATL Lun, FA Buske, K Sabir, ... Genome research 26 (6), 719-731, 2016 | 337 | 2016 |
| Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer J Achinger-Kawecka, F Valdes-Mora, PL Luu, KA Giles, CE Caldon, W Qu, ... Nature communications 11 (1), 320, 2020 | 119 | 2020 |
| Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment R Hoppe*, J Achinger-Kawecka*(co-1st), S Winter, P Fritz, WY Lo, ... European journal of cancer 49 (17), 3598-3608, 2013 | 99 | 2013 |
| Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains A Khoury, J Achinger-Kawecka, SA Bert, GC Smith, HJ French, PL Luu, ... Nature communications 11 (1), 54, 2020 | 85 | 2020 |
| DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity Q Du, GC Smith, PL Luu, JM Ferguson, NJ Armstrong, CE Caldon, ... Cell Reports 36 (12), 2021 | 44 | 2021 |
| Disruption of the 3D cancer genome blueprint J Achinger-Kawecka, SJ Clark Epigenomics 9 (1), 47-55, 2017 | 43 | 2017 |
| Alterations in three-dimensional organization of the cancer genome and epigenome J Achinger-Kawecka, PC Taberlay, SJ Clark Cold Spring Harbor Symposia on Quantitative Biology 81, 41-51, 2016 | 35 | 2016 |
| Integrated epigenomic analysis stratifies chromatin remodellers into distinct functional groups KA Giles, CM Gould, Q Du, K Skvortsova, JZ Song, MP Maddugoda, ... Epigenetics & Chromatin 12, 1-19, 2019 | 33 | 2019 |
| Epigenetic therapies and biomarkers in breast cancer LJ Brown, J Achinger-Kawecka, N Portman, S Clark, C Stirzaker, E Lim Cancers 14 (3), 474, 2022 | 23 | 2022 |
| The assessment of clinical usage and prognostic value of YKL-40 serum levels in patients with rectal cancer without distant metastasis M Fuksiewicz, B Kotowicz, A Rutkowski, J Achinger-Kawecka, ... Technology in Cancer Research & Treatment 17, 1533033818765209, 2018 | 19 | 2018 |
| BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer KA Giles, CM Gould, J Achinger-Kawecka, SG Page, GR Kafer, S Rogers, ... Clinical Epigenetics 13, 1-18, 2021 | 15 | 2021 |
| The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer J Achinger-Kawecka, C Stirzaker, N Portman, E Campbell, KM Chia, Q Du, ... Nature Structural & Molecular Biology, 1-15, 2024 | 8* | 2024 |
| Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma JF Hastings, SL Latham, A Kamili, MS Wheatley, JZR Han, ... Science Advances 9 (9), eabp8314, 2023 | 4 | 2023 |
| PPAR gamma acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding LI Tian, X Jiao, C Wang, A Ertel, R Soccio, ER Chen, B Győrffy, GD Sante, ... Cancer Research 84 (6_Supplement), 3582-3582, 2024 | | 2024 |
| Characterisation and reproducibility of the HumanMethylationEPIC v2. 0 BeadChip for DNA methylation profiling TJ Peters, B Meyer, L Ryan, J Achinger-Kawecka, J Song, EM Campbell, ... BMC genomics 25 (1), 251, 2024 | | 2024 |
| The 2023 generation J Achinger-Kawecka, S Correa, J Hu, G Li, RGH Lindeboom, S Misale, ... Nature Cancer 4 (12), 1630-1635, 2023 | | 2023 |
| Identification of microRNAs for the prediction of breast cancer treatment outcome J Achinger-Kawecka | | 2014 |
| Increased miR-126 and miR-375 expression in primary ER-positive breast cancer predict longer relapse-free time following treatment with tamoxifen. R Hoppe, J Achinger-Kawecka, S Winter, P Fritz, WY Lo, W Schroth, ... Cancer Research 73 (8_Supplement), 1938-1938, 2013 | | 2013 |
susan j clarkprofessor Garvan institute of medical researchVerified email at garvan.org.au
